Individualized Homeopathic and Organopathic Supportive Management of Sickle Cell Disorder: A Case Series of Six Patients from a Particularly Vulnerable Tribal Group in India

Nisanth K.M. Nambison; Narendra Sharma; Abhishek D. Dwivedi; Nisha Chakravarty

doi:10.1055/s-0043-1776908

Homeopathy, Inhaltsverzeichnis

Homeopathy 2024; 113(04): 253-261
DOI: 10.1055/s-0043-1776908

Clinical Case Series

Individualized Homeopathic and Organopathic Supportive Management of Sickle Cell Disorder: A Case Series of Six Patients from a Particularly Vulnerable Tribal Group in India

Nisanth K.M. Nambison

¹Department of AYUSH, Government Homeopathic Medical College and Hospital, Government of Madhya Pradesh, Bhopal, Madhya Pradesh, India

,

Narendra Sharma

¹Department of AYUSH, Government Homeopathic Medical College and Hospital, Government of Madhya Pradesh, Bhopal, Madhya Pradesh, India

,

Abhishek D. Dwivedi

¹Department of AYUSH, Government Homeopathic Medical College and Hospital, Government of Madhya Pradesh, Bhopal, Madhya Pradesh, India

,

Nisha Chakravarty

¹Department of AYUSH, Government Homeopathic Medical College and Hospital, Government of Madhya Pradesh, Bhopal, Madhya Pradesh, India

› Institutsangaben

Abstract

Background Sickle cell disorder (SCD) is a hereditary blood disease characterized by an abnormality in the oxygen-carrying protein hemoglobin present in red blood cells. Genetic abnormality causes these cells to become sickle-shaped, with shorter lifespan. Vaso-occlusive crisis is a major symptom of SCD: it is a sudden and severe episode of pain, and occurs when sickle-shaped cells block blood flow. This blockage can lead to tissue damage, inflammation and pain.

Objectives This case series aims to observe the clinical outcomes from prescribing individualized homeopathic medicines along with organopathic supportive medicine in the management of SCD through the analysis of case studies of six patients from a particularly vulnerable tribal group (PVTG) in India that manifests genetic predisposition for the disease.

Method The patients were administered individualized homeopathic and organopathic supportive medicines, after a comprehensive door-to-door survey and subsequent screening, conducted between October 2020 and May 2023 in the Dindori and Mandla districts of the central Indian state, Madhya Pradesh. Clinical symptoms, laboratory parameters including hemoglobin, along with scores from a visual analogue scale (VAS) for pain and from the World Health Organization Quality of Life (WHOQoL) Questionnaire, were determined.

Results Individualized homeopathic and organopathic supportive management led to improvements in clinical symptoms for all six patients. Laboratory test results showed a statistically significant increase in hemoglobin level associated with treatment. The VAS for pain indicated decreased pain frequency and severity. WHOQoL scores also improved, indicating enhanced well-being for each patient. No adverse effects were reported during treatment.

Conclusion This study suggests that individualized homeopathic medicine and organopathic supportive management have a beneficial role in managing SCD and may be valuable in the context of PVTGs in India. To establish a more comprehensive understanding of its efficacy, further studies should involve larger cohorts to allow for a thorough evaluation, including comparative analyses with standard therapies.

Keywords

sickle cell disorder - particularly vulnerable tribal group - Rhus tox - Arsenicum album - Bryonia alba - China - Natrium mur

Volltext

Referenzen

References
1 Centers for Disease Control and Prevention. What is Sickle Cell Disease?. Published August 18, 2022 . Accessed December 24, 2022 at: https://www.cdc.gov/ncbddd/sicklecell/facts.html
2 National Heart, Lung, and Blood Institute. Sickle cell disease—what is sickle cell disease?. Accessed December 24, 2022 at: https://www.nhlbi.nih.gov/health/sickle-cell-disease
3 National Human Genome Research Institute. About Sickle Cell Disease. Genome.gov. Accessed December 24, 2022 at: https://www.genome.gov/Genetic-Disorders/Sickle-Cell-Disease
4 Hoban MD, Orkin SH, Bauer DE. Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease. Blood 2016; 127: 839-848
5 Inusa BPD, Hsu LL, Kohli N. et al. Sickle cell disease-genetics, pathophysiology, clinical presentation and treatment. Int J Neonatal Screen 2019; 5: 20
6 Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480-487
7 Mangla A, Ehsan M, Agarwal N, Maruvada S. Sickle cell anemia. In: StatPearls. StatPearls Publishing; 2022. . Accessed December 24, 2022.
8 Rao VR. Genetics and epidemiology of sickle cell anemia in India. Indian J Med Sci 1988; 42: 218-222
9 Colah RB, Mukherjee MB, Martin S, Ghosh K. Sickle cell disease in tribal populations in India. Indian J Med Res 2015; 141: 509-515
10 Urade BP. Sickle cell gene (HbS) scenario in tribal India. J Health Med Inform 2012; 3: 114
11 Lehmann H, Cutbush M. Sickle-cell trait in southern India. BMJ 1952; 1: 404-405
12 Saxena D, Yasobant S, Golechha M. Situational analysis of sickle cell disease in Gujarat, India. Indian J Community Med 2017; 42: 218-221
13 Ministry of Tribal Affairs, Government of India. Accessed February 2, 2023. https://tribal.nic.in/
14 Ministry of Tribal Affairs, Government of India. Name of the particularly vulnerable tribal groups (PTGs) (earlier called as primitive tribal groups)—state/UT wise. Accessed February 2, 2023 at: https://tribal.nic.in/ST/StatewisePvTGsList.pdf
15 da Silva Junior GB, De Francesco Daher E, da Rocha FAC. Osteoarticular involvement in sickle cell disease. Rev Bras Hematol Hemoter 2012; 34: 156-164
16 Mabaera R, West RJ, Conine SJ. et al. A cell stress signaling model of fetal hemoglobin induction: what doesn't kill red blood cells may make them stronger. Exp Hematol 2008; 36: 1057-1072
17 Agrawal RK, Patel RK, Shah V, Nainiwal L, Trivedi B. Hydroxyurea in sickle cell disease: drug review. Indian J Hematol Blood Transfus 2014; 30: 91-96
18 Aliyu ZY, Tumblin AR, Kato GJ. Current therapy of sickle cell disease. Haematologica 2006; 91: 7-10
19 Imaga NOA, Gbenle GO, Okochi VI. et al. Antisickling property of Carica papaya leaf extract. Afr J Biochem Res 2009; 3: 102-106
20 Banerjee A, Chakrabarty SB, Karmakar SR. et al. Can homeopathy bring additional benefits to thalassemic patients on hydroxyurea therapy? Encouraging results of a preliminary study. Evid Based Complement Alternat Med 2010; 7: 129-136
21 Hati AK, Paital B, Naik KN, Mishra AK, Chainy GB, Nanda LK. Constitutional, organopathic and combined homeopathic treatment of benign prostatic hypertrophy: a clinical trial. Homeopathy 2012; 101: 217-223
22 Tanabe P, Spratling R, Smith D, Grissom P, Hulihan M. Understanding the complications of sickle cell disease. Am J Nurs 2019; 119: 26-35
23 Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev 2015; 2015: CD001916
24 Boericke W. Homoeopathic Materia Medica. Accessed August 5, 2023 at: http://homeoint.org/books/boericmm/index.htm
25 Allen TF. Hand Book of Materia Medica and Homoeopathic Therapeutics. Accessed August 5, 2023 at: http://www.homeoint.org/books1/allenhandbook/
26 Billah MA, Khan F, Ghosh S. Exploring organopathy—its applicability and limitations. IAR J Med Sci 2022; 3: 65-70
27 Motiwala FF, Shukla DS, Bhalerao DS. et al. Comparative study of Ferrum phos 6x versus Ferrum phos 6x along with homoeopathic medicine in the management of anaemia—randomized controlled trial in all age group. J Homoeopathy 2022; 4: 1-16
28 Oyedapo OA, Agbedahunsi JM, Cyril-Olutayo CM. Anti-sickling activities of the stem bark of three Khaya species found in Nigeria: K. senegalensis A. Juss., K. grandifoliola (Welw) CDC., and K. ivorensis A. Chev. Niger J Nat Prod Med 2017; 20: 161
29 Allen TF. Hand Book of Materia Medica and Homoeopathic Therapeutics. Papaya vulgaris. Accessed February 28, 2023 at: http://www.homeoint.org/books1/allenhandbook/p/pap-v.htm
30 Boericke W. Homoeopathic Materia Medica. Ceanothus americanus. Accessed February 28, 2023 at: http://homeoint.org/books/boericmm/c/cean.htm
31 Boericke W. Homoeopathic Materia Medica. Rhus toxicodendron. Accessed July 31, 2023 at: http://homeoint.org/books/boericmm/r/rhus-t.htm
32 Boericke W. Homoeopathic Materia Medica. Arsenicum album. Accessed July 31, 2023 at: http://homeoint.org/books/boericmm/a/ars.htm
33 Platt OS. The acute chest syndrome of sickle cell disease. N Engl J Med 2000; 342: 1904-1907
34 Boericke W. Homoeopathic Materia Medica. China officinalis. Accessed July 31, 2023 at: http://homeoint.org/books/boericmm/c/chin.htm
35 Boericke W. Homoeopathic Materia Medica. Bryonia alba. Accessed July 31, 2023 at: http://homeoint.org/books/boericmm/b/bry.htm
36 Boericke W. Homoeopathic Materia Medica. Natrium muriaticum. Accessed July 31, 2023, at http://homeoint.org/books/boericmm/n/nat-m.htm
37 Nanda LK. Homeopathy in rheumatoid arthritis—an evaluation by double-blind clinical trial. Allg Homoopath Ztg 2005; 250: 81
38 Ranasinghe P, Ranasinghe P, Abeysekera WPKM. et al. In vitro erythrocyte membrane stabilization properties of Carica papaya L. leaf extracts. Pharmacognosy Res 2012; 4: 196-202
39 Gul K, Singh AK, Jabeen R. Nutraceuticals and functional foods: the foods for the future world. Crit Rev Food Sci Nutr 2016; 56: 2617-2627
40 Boericke W. Pocket Manual of Homoeopathic Materia Medica. Delhi: Motilal Banarsidass; 1993

Zusatzmaterial

Supplementary Material